Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Riccardo Sartoris(Hôpital Beaujon), Kornelius Schulze(Universität Hamburg), Antonio D’Alessio(Hammersmith Hospital), Fabian Finkelmeier(Goethe University Frankfurt), Katharina Pomej(Medical University of Vienna), Florian Hucke(Klinikum Klagenfurt), Rudolf Stauber(Medical University of Graz), Johann von Felden(Universität Hamburg), Sabrina Sidali(Hôpital Beaujon), Claudia Angela Maria Fulgenzi(Università Campus Bio-Medico), Vera Himmelsbach(Goethe University Frankfurt), Sara De Dosso(Institute of Oncology Research), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Arndt Vogel(Princess Margaret Cancer Centre), Mohamed Bouattour(Hôpital Beaujon), Michael Trauner(Medical University of Vienna), Henning Wege(Universität Hamburg), Maxime Ronot(Hôpital Beaujon), Kateryna Shmanko(Johannes Gutenberg University Mainz), Anja Krall, Andreas Teufel(Johannes Gutenberg University Mainz), Lorenz Balcar(Medical University of Vienna), Wei‐Fan Hsu(China Medical University), Jörg Trojan(Goethe University Frankfurt), Iuliana Pompilia Radu, Matthias P. Ebert(Heidelberg University), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Jean‐François Dufour(Universidad Iberoamericana), Alexander Siebenhüner(University Hospital Zurich), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Dirk‐Thomas Waldschmidt(University of Cologne), Arndt Weinmann(Johannes Gutenberg University Mainz)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k